The proposed role of MDM2/p53 in antitumor immunity. MDM2 inhibition and the consecutive increase in p53 lead to enhanced MHC I and II expression, activation of ERV with consecutive double stranded RNA release and type 1 and 3 IFN responses, IL-15 production, and TRAIL-R1/2 transcription in malignant cells. The direct effects of MDM2 inhibition or MDM2 deletion in effector T cells include increased production of perforin and other cytotoxic molecules.